Loading
The first gene-expression subtypes of pancreatic cancer, classical, quasi-mesenchymal and exocrine-like, came from pooling tumour and cell-line profiles, and the authors showed the types differ in outcome and in how cell lines respond to drugs.
Because tumour specimens were scarce, transcriptional profiles of primary pancreatic ductal adenocarcinoma samples from several studies were combined with human and mouse cell lines. Three subtypes were defined, classical, quasi-mesenchymal and exocrine-like, with evidence for clinical outcome and therapeutic response differences between them. Gene signatures for the subtypes and preclinical model systems for finding subtype-specific therapies were presented.
It opened the subtype programme that Moffitt, Bailey and COMPASS refined; the classical versus mesenchymal or basal split has survived every re-analysis.
Shares RNA sequencing & expression profiling, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS, Pancreatic ductal adenocarcinoma.
Shares RNA sequencing & expression profiling, Pancreatic ductal adenocarcinoma.
Shares KRAS, Pancreatic ductal adenocarcinoma.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS, Pancreatic ductal adenocarcinoma.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS, Pancreatic ductal adenocarcinoma.
Shares KRAS, Pancreatic ductal adenocarcinoma.